This bill requires health insurers and health plans in Maryland to cover salpingectomy (surgery to remove fallopian tubes) specifically for ovarian cancer prevention as a standard benefit, with no out-of-pocket costs like copays or deductibles for patients. It applies to all health insurance policies issued in Maryland after January 1, 2027, directly affecting women who might choose this preventive surgery and the insurers providing coverage. The key provision bans cost-sharing for this procedure, except when an individual is enrolled in a high-deductible health plan meeting federal criteria. This ensures access to a proven preventive measure without financial barriers for most patients.
HB 797 prohibits employers from discriminating against fire and rescue public safety employees who use medical cannabis, provided they have a valid written certification from a licensed healthcare provider under Maryland's medical cannabis program. The bill modifies existing law to clarify that an employer cannot take adverse employment actions (like termination or denial of promotion) solely due to medical cannabis use, as long as the employee meets the state's certification requirements. It updates definitions in Maryland law to ensure fire and rescue employees qualify for the same protections as other medical cannabis patients under the existing program. The law does not override workplace safety rules or require employers to accommodate cannabis use during work hours.
HB 1426 creates a new permit for clinical research pharmacies in Maryland, which are facilities specifically designed to conduct clinical trials. It allows healthcare providers to own these pharmacies under strict conditions, including requiring a licensed pharmacist to be on-site during all operating hours and prohibiting owners from receiving payment for patient referrals. The bill also exempts clinical trials conducted by corporations or entities from being classified as "practice of medicine," meaning trial staff no longer need individual medical licenses for their trial-related work. This change aims to streamline clinical research by removing a regulatory barrier that previously required individual licensing for trial staff.
HB 222 requires Maryland public schools and colleges to update policies and education programs to address opioid overdoses. It mandates schools to store naloxone, allow authorized staff and students to possess it, and provide liability protection for good-faith use during overdoses. The bill also adds naloxone's life-saving role to K-12 drug prevention curricula (starting in third grade) and requires annual parent notifications about school naloxone policies. Additionally, schools must report overdose incidents requiring naloxone use to the State Department. This affects all public K-12 schools and state-funded colleges.
HB 494 requires health insurance companies, nonprofit health service plans, and health maintenance organizations (HMOs) operating in Maryland to structure their reimbursements to primary care providers in a way that meets annual investment targets set by the state. Starting February 1, 2026, these entities must report their progress toward meeting these targets when filing new or updated premium rates with the Maryland Insurance Commissioner. The bill amends insurance code sections to mandate this reporting requirement as part of premium rate filings. It takes effect October 1, 2026, focusing on transparency and accountability for primary care funding.
SB 348 requires hospitals and freestanding birthing centers in Maryland to provide specific postpartum support to individuals who have experienced high-risk pregnancies. It mandates that facilities complete referral forms for local health departments, provide resources about postpartum complications (including cardiovascular conditions, chronic disease, substance misuse, and mental health), and call birthing parents 24 to 72 hours after discharge to assess their status. The bill also requires annual reports from health departments detailing referrals made through this process. These provisions apply to all facilities delivering newborns following high-risk pregnancies and take effect October 1, 2026.
HB 598 creates a temporary license for internationally trained physicians to practice medicine in Maryland under specific conditions. It allows the State Board of Physicians to issue a 3-year license (non-renewable) to doctors who hold a WHO-recognized medical degree outside the U.S., completed 2 years of equivalent postgraduate training, practiced medicine for 5 of the last 7 years abroad, passed U.S. medical exams (USMLE Steps 1-3), and meet other criteria like English proficiency and Maryland residency. The license requires physicians to pursue full licensure through board-established pathways after the temporary period ends. This directly affects internationally trained doctors seeking to work in Maryland’s healthcare system, providing a structured but limited pathway to practice.
HB 633 requires Maryland health insurers, nonprofit health plans, and health maintenance organizations to cover salpingectomy (surgical removal of fallopian tubes) as a preventive measure for ovarian cancer. It prohibits these insurers from charging copayments, coinsurance, or deductibles for this specific procedure, ensuring no out-of-pocket costs for covered individuals. The exception applies only to high-deductible health plans under federal law, allowing the deductible to apply to the procedure in those cases. This law directly affects women eligible for preventive care and the health insurance providers operating in Maryland.
SB 489 modifies Maryland's licensing rules for physicians trained at international medical schools. It exempts applicants who provide evidence of completing two years of postgraduate training accredited by ACGME-I or another board-recognized body from standard educational requirements. These physicians would be permitted to practice medicine only during their initial license term under mandatory supervision, as specified by the Board. The bill takes effect October 1, 2026, directly affecting international medical graduates meeting these specific training criteria.
HB 813 authorizes Maryland's Medicaid program (Maryland Medical Assistance Program) to cover comprehensive obesity treatment, including intensive behavioral therapy, bariatric surgery, and FDA-approved weight management medications, starting January 1, 2027. The bill requires the Maryland Department of Health to notify Medicaid recipients if it chooses to provide this coverage and mandates a report to the legislature by November 1, 2027, on implementation progress. This directly affects Medicaid recipients with obesity by expanding covered treatments beyond current scope. The program may use standard utilization management processes (like for other conditions) to assess medical necessity but is not required to offer the coverage.
